Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Dipna Pharmachem's Enterprise Value is ₹249 Mil.
Dipna Pharmachem's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was ₹37 Mil. Therefore, Dipna Pharmachem's EV-to-EBIT ratio for today is 6.65.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Dipna Pharmachem's Enterprise Value is ₹249 Mil.
Dipna Pharmachem's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was ₹38 Mil. Therefore, Dipna Pharmachem's EV-to-EBITDA ratio for today is 6.63.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Dipna Pharmachem's Enterprise Value is ₹249 Mil.
Dipna Pharmachem's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 was ₹1,249 Mil. Therefore, Dipna Pharmachem's EV-to-Revenue ratio for today is 0.20.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Dipna Pharmachem (BOM:543594) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Dipna Pharmachem's current Enterprise Value is ₹249 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Dipna Pharmachem's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was ₹37 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Dipna Pharmachem's current Enterprise Value is ₹249 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Dipna Pharmachem's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was ₹38 Mil.
Dipna Pharmachem's current Enterprise Value is ₹249 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Dipna Pharmachem's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 was ₹1,249 Mil.
Dipna Pharmachem's current Enterprise Value is ₹249 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Dipna Pharmachem's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was ₹-183 Mil.
Dipna Pharmachem's current Enterprise Value is ₹249 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Dipna Pharmachem's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was ₹-184 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dipna Pharmachem Enterprise Value Related Terms
Dipna Pharmachem Enterprise Value Historical Data
* Premium members only.
The historical data trend for Dipna Pharmachem's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dipna Pharmachem Enterprise Value Competitor Comparison
For the Pharmaceutical Retailers subindustry, Dipna Pharmachem's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dipna Pharmachem Enterprise Value vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Dipna Pharmachem's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Dipna Pharmachem's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Dipna Pharmachem's Enterprise Value for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dipna Pharmachem (BOM:543594) has a Enterprise Value of ₹249 Mil as of Aug. 08, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Dipna Pharmachem and its competitors.
Is Dipna Pharmachem's Enterprise Value too high?
Dipna Pharmachem's current Enterprise Value is ₹249 Mil. Overall, Dipna Pharmachem has a GF Score™ of 62/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Dipna Pharmachem's Enterprise Value compare to competitors?
Dipna Pharmachem's Enterprise Value of ₹249 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Healthcare Providers & Services company?
A good Enterprise Value depends on the Healthcare Providers & Services industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Dipna Pharmachem and its competitors. Dipna Pharmachem's current Enterprise Value is ₹249 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dipna Pharmachem stock overvalued right now?
Based on GuruFocus' analysis, Dipna Pharmachem (BOM:543594) is currently considered Possible Value Trap. The stock's GF Value™ is ₹9.16, compared to a current price of ₹4.89 — trading 46.6% below its estimated fair value. The current Enterprise Value is ₹249 Mil. Dipna Pharmachem's overall GF Score™ is 62/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Dipna Pharmachem (BOM:543594), the current Enterprise Value is ₹249 Mil as of Aug. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dipna Pharmachem (BOM:543594) Overvalued in 2026?
Based on GuruFocus' analysis, Dipna Pharmachem stock appears to be undervalued.
The current stock price of ₹4.89 is trading 46.6% below its estimated GF Value™ of ₹9.16.
GuruFocus considers Dipna Pharmachem to be Possible Value Trap.
Key valuation signals for BOM:543594:
Enterprise Value: ₹249 Mil
GF Value™: ₹9.16 vs. price of ₹4.89 (46.6% below fair value)
No single metric tells the full story. See the BOM:543594 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dipna Pharmachem Ltd is engaged in the trading and distribution of a wide range of pharmaceutical raw materials which is also known as APIs (Active Pharmaceutical Ingredients), Excipient and chemical formulation products. The company's product portfolio comprises of Hydrocortisone Acetate, Aceclofenac, Asprin, Levofloxacin, and others.
62GF Score
Get the complete analysis for BOM:543594
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:543594 has been successfully added to your 
